Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, recently announced the grant of an equity award to its new President and Chief Executive Officer, Harout Semerjian. The award consists of stock options to purchase 11,000,000 shares of common stock, offered as an inducement for his employment. The options, granted on August 7, 2025, come with an exercise price of $1.30 per share, matching the closing price of the stock on the grant date, and have a ten-year term. Of these, 7,000,000 options will vest over four years, with an initial 12.5% vesting six months after the start of his employment and the rest in equal monthly installments over the next 42 months. The remaining 4,000,000 options will vest with 25% on the one-year anniversary and the rest over 36 months in equal installments. This grant was made in line with Nasdaq Listing Rule 5635(c)(4) and falls under the terms of the company's 2018 Inducement Award Plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.